Zelira Therapeutics Limited announced that a Zelira-funded team of researchers at Curtin University (Australia) have developed a new technology that improves delivery of cannabidiol (CBD) based drugs into the brains of mice by up to 40-times. This technology has potential for cannabinoid-based therapies to treat neurological disorders such as Alzheimer's disease, multiple sclerosis, and traumatic brain injury. Published in the leading peer reviewed open access scientific journal PLOS ONE, the Curtin University research team created tiny capsules containing cannabinoids which, when taken orally, were absorbed by the body faster and penetrated the brain quicker in mice models with neurological diseases, than when delivered in liquid form. This research was a collaborative effort involving researchers from CHIRI, the Curtin Medical School and the School of Population Health at Curtin University, the University of Newcastle and the University of Otago.